MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.28 -0.78

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.28

Max

1.31

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+134.38% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-21M 82M
Vorheriger Eröffnungskurs	2.06
Vorheriger Schlusskurs	1.28

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Jan. 2026, 23:29 UTC

Heiße Aktien

Stocks to Watch: Atossa Therapeutics, Union Pacific

16. Jan. 2026, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16. Jan. 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16. Jan. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16. Jan. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

16. Jan. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Auto & Transport Roundup: Market Talk

16. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. Jan. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16. Jan. 2026, 21:48 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16. Jan. 2026, 21:41 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16. Jan. 2026, 21:38 UTC

Akquisitionen, Fusionen, Übernahmen

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16. Jan. 2026, 20:44 UTC

Ergebnisse

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16. Jan. 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16. Jan. 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16. Jan. 2026, 19:12 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16. Jan. 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16. Jan. 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16. Jan. 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16. Jan. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16. Jan. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16. Jan. 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Jan. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16. Jan. 2026, 16:32 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16. Jan. 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

134.38% Vorteil

12-Monats-Prognose

Durchschnitt 3 USD 134.38%

Hoch 4 USD

Tief 2 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.